A 32-year-old man is found to be HBsAg positive, HBeAg negative, with HBV DNA of 12,000 IU/mL and elevated ALT on two occasions 6 months apart. Anti-HBe is positive. He has no cirrhosis on liver biopsy. This serological pattern is consistent with which phase of chronic HBV infection, and what treatment is recommended?
- A Inactive carrier state — no treatment, monitor every 6–12 months
- B HBeAg-negative chronic hepatitis B (immune reactive phase) — antiviral therapy with entecavir or tenofovir ✓
- C HBeAg-positive immune active phase — pegylated interferon-alpha therapy
- D Immune tolerant phase — no treatment, normal ALT despite high viral load
Explanation
HBeAg-negative chronic hepatitis B occurs due to precore or basal core promoter mutations in HBV that prevent HBeAg expression while viral replication continues. Anti-HBe is positive, HBeAg negative, but HBV DNA is elevated (>2,000 IU/mL) with elevated ALT and liver inflammation — this is the HBeAg-negative immune reactive (active) phase, not the inactive carrier state. Inactive carriers have HBV DNA <2,000 IU/mL AND normal ALT persistently. This phase requires antiviral treatment (entecavir or tenofovir disoproxil fumarate/TDF or tenofovir alafenamide/TAF) because liver inflammation continues despite negative HBeAg. Pegylated interferon is an option for finite treatment in non-cirrhotic patients.
Reference: Ananthanarayan & Paniker's Textbook of Microbiology, 11th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.